RGD Cyclic Peptidomimetics for Targeted Integrin Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for cancer, particularly those targeting integrins, face challenges in specificity and efficacy due to the lack of effective molecules that can selectively bind to integrins on cancer cells and endothelial cells, leading to inadequate tumor targeting and treatment outcomes.
Innovation Solution
Development of RGD-containing cyclic peptidomimetics that act as αvβ3 and αvβ5 integrin ligands, conjugated with payloads such as fluorescent probes, photosensitizers, chelating agents, or cytotoxic agents, allowing for targeted diagnostic and therapeutic applications by selectively binding to tumor tissues.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If RGD peptides are used to target integrins on tumor cells and endothelial cells, then tumor targeting capability is improved, but specificity is insufficient due to binding with non-target integrins
Solution Approach 1:
The patent applies local quality by modifying specific positions within the RGD peptide sequence (positions -2, -1, +2, +3 relative to the RGD core) to create position-specific substitutions that enhance affinity for αvβ3 integrin while maintaining selectivity. This localized modification approach allows the peptide to have different binding characteristics at different positions, improving both targeting capability and specificity simultaneously.
Solution Approach 2:
The patent systematically varies multiple parameters including amino acid substitutions at specific positions, cyclic vs linear configurations, and conjugation to different payloads (fluorophores, radionuclides, cytotoxic agents). These parameter changes enable optimization of binding affinity and selectivity for αvβ3 integrin over other integrin subtypes, resolving the contradiction between targeting capability and specificity.
2Adaptability or versatility
If conventional chemotherapy agents are used, then treatment coverage is broad, but toxicity to healthy cells increases
Solution Approach 1:
The patent segments the therapeutic approach by separating the targeting function (RGD peptidomimetic) from the therapeutic function (payload). The RGD peptidomimetic specifically targets tumor cells expressing αvβ3 integrin, while the payload (cytotoxic agent, radionuclide, or photosensitizer) delivers the therapeutic effect only at the target site. This segmentation enables broad treatment coverage through various payload options while minimizing toxicity to healthy cells through selective targeting.
Solution Approach 2:
The RGD peptidomimetic acts as an intermediary that mediates between the therapeutic payload and the target cell. It selectively binds to αvβ3 integrin on tumor cells, bringing the payload into proximity with the target cell only when and where needed. This intermediary function enables broad therapeutic coverage while protecting healthy cells from unnecessary exposure to toxic payloads.
3Reliability
If RGD peptides are conjugated with payloads for targeted therapy, then treatment efficacy is improved, but molecular complexity increases
Solution Approach 1:
The patent creates a universal platform where the RGD peptidomimetic core can be conjugated to multiple different payloads (fluorophores for imaging, radionuclides for radiotherapy, photosensitizers for PDT, cytotoxic agents for chemotherapy). This multi-functional design improves treatment efficacy by allowing selection of the most appropriate payload for each clinical scenario while maintaining a consistent, optimized targeting moiety. The modular nature of this universal platform actually simplifies the overall development process despite the variety of applications.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The RGD-containing cyclic peptidomimetics demonstrate enhanced specificity and accumulation in tumors, enabling effective visualization, photodynamic therapy, radio imaging, and targeted chemotherapy with reduced toxicity and improved treatment outcomes.
Implementation Method 1
The arginine-glycine-aspartic acid (Arg-Gly-Asp; RGD) motif of extracellular matrix (ECM) components such as fibronectin binds to integrins. Data obtained by phage display methods screening for RGD-containing peptides have shown their selective binding to endothelial lining of tumor blood vessels.
Implementation Method 2
Conjugation of the anticancer drug doxorubicin or a pro-apoptotic peptide to an αvβ3 integrin-binding RGD peptide yields compounds that are more active and less toxic than unmodified drugs when tested against xenograft tumors in mice.
Implementation Method 3
WO 2008/023378 discloses a conjugate of an RGD-containing peptide or an RGD peptidomimetic and a photosensitizer selected from a porphyrin, a chlorophyll or a bacteriochlorophyll.
Implementation Method 4
Conjugate of the RGD-containing cyclic peptidomimetic and a moiety of a payload selected from a fluorescent probe, a photosensitizer, a chelating agent or a cytotoxic agent
Data Source
AI summary
The invention provides RGD-containing cyclic peptidomimetics; conjugates of said peptidomimetics and a moiety of a payload selected from fluorescent probes, photosensitizers, chelating agents, or cytotoxic agents; and pharmaceutical compositions comprising these conjugates. The conjugates of the invention are useful both for diagnostic purposes and treatment of various diseases, disorders and conditions. More specifically, conjugates comprising fluorescent probes can be used for diagnostic purposes, e.g., visualization of organs and tissues, and diagnosis of tumors; conjugates comprising photosensitizers can be used for photodynamic therapy of both tumors and nonneoplastic tissues; conjugates comprising chelating agents can be used in radioimaging or radiotherapy; and conjugates comprising cytotoxic agents can be used for targeted chemotherapy.